The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor

•Different peripheral blood parameters have emerged as prognostic biomarkers in lung cancer, but their predictive role in ALK-positive NSCLC remains unclear.•A new comprehensive marker called the Pan-Immune-Inflammatory Value (PIV), has recently showed prognostic value in some solid tumors.•PIV was firstly showed an independent predictor of PFS and OS in patients with ALK-positive advanced NSCLC patients who received first-line ALK TKIs.